Clinical trial
Molecular Analysis for Therapy Choice (MATCH)
NCT02465060 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Molecular Analysis for Therapy Choice (MATCH)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- August 17, 2015
- Completion date
- December 31, 2027
- Enrollment
- 6,452 (estimated)
- Sites
- 1,410
Conditions
As the registry lists them; a condition with its own page is linked.
advanced lymphoma, advanced malignant solid neoplasm, bladder carcinoma, breast carcinoma, cervical carcinoma, colon carcinoma, colorectal carcinoma, endometrial carcinoma, esophageal carcinoma, exocrine pancreas carcinoma, gastric carcinoma, glioma, head and neck carcinoma, hematopoietic and lymphoid cell neoplasm, kidney carcinoma, liver carcinoma, lung carcinoma, lymphoma, malignant uterine corpus neoplasm, malignant uterine neoplasm, melanoma, multiple myeloma, ovarian carcinoma, prostate carcinoma, rectal carcinoma, recurrent bladder carcinoma, recurrent breast carcinoma, recurrent cervical carcinoma, recurrent colon carcinoma, recurrent colorectal carcinoma, recurrent esophageal carcinoma, recurrent gastric carcinoma, recurrent glioma, recurrent head and neck carcinoma, recurrent liver carcinoma, recurrent lung carcinoma, recurrent lymphoma, recurrent malignant solid neoplasm, recurrent malignant uterine corpus neoplasm, recurrent melanoma, recurrent multiple myeloma, recurrent ovarian carcinoma, recurrent pancreatic carcinoma, recurrent prostate carcinoma, recurrent rectal carcinoma, recurrent skin carcinoma, recurrent thyroid gland carcinoma, refractory lymphoma, refractory malignant solid neoplasm, refractory multiple myeloma, skin carcinoma, thyroid gland carcinoma